It is evident that cytokines play an important role in the pathogenesis as well as disease progression of IgA nephropathy (IgAN). Several gene polymorphisms of the pertinent cytokines have an influence on the level of cytokine production. Interleukin-1 receptor antagonist (IL-1ra) gene polymorphism has been found to affect disease susceptibility and activity in several inflammatory diseases. In the present study, we analyzed polymorphism of the variable number tandem repeat (VNTR) of IL-1ra in patients diagnosed as having IgAN (n = 106) and normal controls (n = 74). The allele frequency of IL-1ra polymorphism in IgAN patients was not statistically different from that of the control group. There was no significant difference in the carriage rate of the two-repeat allele (IL1RN*2) between IgAN patients and the control group (8.5 vs. 6.8%). The carriage rate of IL1RN*2 was significantly higher in IgAN patients with severe proteinuria (≧1.6 g/day) or increased serum creatinine level (≧2.0 mg/dl; p < 0.05). Furthermore, the carriage rate of IL1RN*2 was significantly higher in patients with severe mesangial cell proliferation (p < 0.01). Our results suggest that IL-1ra polymorphisms are not associated with the development of IgAN in Japanese patients but the presence of IL1RN*2 may be associated with increased disease activity.

Keywords:
Interleukin-1 receptor antagonist gene polymorphism, IL1RN*2, IgA nephropathy
1.
Chen A, Chen WP, Sheu LF, Lin CY: Pathogenesis of IgA nephropathy: In vitro activation of human mesangial cells by IgA immune complex leads to cytokine secretion. J Pathol 1994;173:119–126.
2.
Wardle EN: Cytokines as growth factors and glomerulonephritis. Nephron 1991;57:257–261.
3.
Border WA, Noble NA: From serum sickness to cytokines. Lab Invest 1993;68:125–128.
4.
Tarlow JK, Blakemore AIF, Lennard A, Solari R, Hughes HN, Steinkasserer A, Duff GW: Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat. Hum Genet 1993;91:403–404.
5.
Shu KH, Lee SH, Cheng CH, Wu MJ, Lian JD: Impact of interleukin-1 receptor antagonist and tumor necrosis factor-α gene polymorphism on IgA nephropathy. Kidney Int 2000;58:783–789.
6.
Liu ZH, Cheng ZH, Yu YS, Tang Z, Li LS: Interleukin-1 receptor antagonist allele: Is it a genetic link between Henoch-Schönlein nephritis and IgA nephropathy? Kidney Int 1997;51:1938–1942.
7.
Blakemore AIF, Tarlow JK, Cork MJ, Gordan C, Emery P, Duff GW: Interleukin-1 receptor antagonist polymorphism as a disease severity factor in systemic lupus erythematosus. Arthritis Rheum 1994;37:1380–1385.
8.
Mansfield JC, Holden H, Tarlow JK, McDowell TL, Wilson AG, Di Giovine FS, Holdsworth CD, Duff GW: Novel genetic polymorphism between ulcerative colitis and the anti-inflammatory cytokine interleukin-1 receptor antagonist. Gastroenterology 1994;106:637–642.
9.
Blakemore AIF, Cox A, Gonzalez AM, Maskill JK, Hughes ME, Wilson RM, Ward JD, Duff GW: Interleukin-1 receptor antagonist allele (IL1RN*2) associated with nephropathy in diabetes mellitus. Hum Genet 1996;97:369–374.
10.
Tountas NA, Casini-Raggi V, Yang H, Di Giovine FS, Vecchi M, Kam L, Melani L, Pizarro TT, Rotter JI, Cominelli F: Functional and ethnic association of allele 2 of the interleukin-1 receptor antagonist gene in ulcerative colitis. Gastroenterology 1999;117:806–813.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.